254 related articles for article (PubMed ID: 17911173)
1. Lack of mutations in the thyroid hormone receptor (TR) alpha and beta genes but frequent hypermethylation of the TRbeta gene in differentiated thyroid tumors.
Joseph B; Ji M; Liu D; Hou P; Xing M
J Clin Endocrinol Metab; 2007 Dec; 92(12):4766-70. PubMed ID: 17911173
[TBL] [Abstract][Full Text] [Related]
2. Silencing of the maternally imprinted tumor suppressor ARHI contributes to follicular thyroid carcinogenesis.
Weber F; Aldred MA; Morrison CD; Plass C; Frilling A; Broelsch CE; Waite KA; Eng C
J Clin Endocrinol Metab; 2005 Feb; 90(2):1149-55. PubMed ID: 15546898
[TBL] [Abstract][Full Text] [Related]
3. Caveolin-1 and caveolin-2,together with three bone morphogenetic protein-related genes, may encode novel tumor suppressors down-regulated in sporadic follicular thyroid carcinogenesis.
Aldred MA; Ginn-Pease ME; Morrison CD; Popkie AP; Gimm O; Hoang-Vu C; Krause U; Dralle H; Jhiang SM; Plass C; Eng C
Cancer Res; 2003 Jun; 63(11):2864-71. PubMed ID: 12782592
[TBL] [Abstract][Full Text] [Related]
4. Frizzled-1 is down-regulated in follicular thyroid tumours and modulates growth and invasiveness.
Ulivieri A; Lavra L; Dominici R; Giacomelli L; Brunetti E; Sciacca L; Trovato M; Barresi G; Foukakis T; Jia-Jing L; Larsson C; Bartolazzi A; Sciacchitano S
J Pathol; 2008 May; 215(1):87-96. PubMed ID: 18306168
[TBL] [Abstract][Full Text] [Related]
5. A tumor suppressor role for thyroid hormone beta receptor in a mouse model of thyroid carcinogenesis.
Kato Y; Ying H; Willingham MC; Cheng SY
Endocrinology; 2004 Oct; 145(10):4430-8. PubMed ID: 15231697
[TBL] [Abstract][Full Text] [Related]
6. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
[TBL] [Abstract][Full Text] [Related]
7. Expression of thyroid hormone receptors A and B in developing rat tissues; evidence for extensive posttranscriptional regulation.
Keijzer R; Blommaart PJ; Labruyère WT; Vermeulen JL; Doulabi BZ; Bakker O; Tibboel D; Lamers WH
J Mol Endocrinol; 2007 May; 38(5):523-35. PubMed ID: 17496154
[TBL] [Abstract][Full Text] [Related]
8. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
Elisei R; Shiohara M; Koeffler HP; Fagin JA
Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
[TBL] [Abstract][Full Text] [Related]
10. Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis.
Brown TC; Juhlin CC; Healy JM; Prasad ML; Korah R; Carling T
JAMA Surg; 2014 Nov; 149(11):1146-52. PubMed ID: 25229773
[TBL] [Abstract][Full Text] [Related]
11. The Ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPARgamma fusion.
Foukakis T; Au AY; Wallin G; Geli J; Forsberg L; Clifton-Bligh R; Robinson BG; Lui WO; Zedenius J; Larsson C
J Clin Endocrinol Metab; 2006 Mar; 91(3):1143-9. PubMed ID: 16352687
[TBL] [Abstract][Full Text] [Related]
12. Infrequent CDKN2 mutation in human differentiated thyroid cancers.
Tung WS; Shevlin DW; Bartsch D; Norton JA; Wells SA; Goodfellow PJ
Mol Carcinog; 1996 Jan; 15(1):5-10. PubMed ID: 8561866
[TBL] [Abstract][Full Text] [Related]
13. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors.
Dahia PL; Marsh DJ; Zheng Z; Zedenius J; Komminoth P; Frisk T; Wallin G; Parsons R; Longy M; Larsson C; Eng C
Cancer Res; 1997 Nov; 57(21):4710-3. PubMed ID: 9354427
[TBL] [Abstract][Full Text] [Related]
14. Molecular cloning and mRNA tissue expression of thyroid hormone receptors in yellow catfish Pelteobagrus fulvidraco and Javelin goby Synechogobius hasta.
Chen QL; Luo Z; Tan XY; Pan YX; Zheng JL; Zou M
Gene; 2014 Feb; 536(2):232-7. PubMed ID: 24380707
[TBL] [Abstract][Full Text] [Related]
15. Genetic mutations in thyroid carcinoma.
Taccaliti A; Boscaro M
Minerva Endocrinol; 2009 Mar; 34(1):11-28. PubMed ID: 19209125
[TBL] [Abstract][Full Text] [Related]
16. Studies of allelic loss in thyroid tumors reveal major differences in chromosomal instability between papillary and follicular carcinomas.
Ward LS; Brenta G; Medvedovic M; Fagin JA
J Clin Endocrinol Metab; 1998 Feb; 83(2):525-30. PubMed ID: 9467569
[TBL] [Abstract][Full Text] [Related]
17. Cardiac glucose utilization in mice with mutated alpha- and beta-thyroid hormone receptors.
Esaki T; Suzuki H; Cook M; Shimoji K; Cheng SY; Sokoloff L; Nunez J
Am J Physiol Endocrinol Metab; 2004 Dec; 287(6):E1149-53. PubMed ID: 15304375
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological roles of alterations of tumor suppressor gene p16 in papillary thyroid carcinoma.
Lam AK; Lo CY; Leung P; Lang BH; Chan WF; Luk JM
Ann Surg Oncol; 2007 May; 14(5):1772-9. PubMed ID: 17195959
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
[TBL] [Abstract][Full Text] [Related]
20. The natural protein kinase C alpha mutant is present in human thyroid neoplasms.
Prévostel C; Alvaro V; de Boisvilliers F; Martin A; Jaffiol C; Joubert D
Oncogene; 1995 Aug; 11(4):669-74. PubMed ID: 7651730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
